Next Phase Newsletter

A financial firm based in Asia has created a healthcare-focused US$100 million evergreen fund. The firm seeks to participate in Series A to C rounds and is open to leading or following. Typical investments range from US$0.5 to 2 million, while larger investments can be considered on a case-by-case basis. The firm expects to make 4-5 new deals in the coming 12 months. The firm is currently seeking opportunities from the US and Canada.

The firm considers opportunities broadly across the healthcare field, including biomedicine, medical devices, diagnostics. The firm currently has an increased interest in healthcare IT. When it comes to overseas deals, the firm prefers products that have achieved prototype and clinical proof-of-concept. The firm is opportunistic in terms of disease areas.

The firm is looking for competent and experienced management teams. The firm does not require board representation after investment. As a financially-driven investor, the firm does not typically request regional rights, but it can provide assistance with finding local partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A cross-border venture capital firm with offices in Cambridge, MA and in Tokyo, Japan is currently investing from its newest $80 million fund closed in 2017. Its LPs include pharmaceutical companies. Typically the firm makes an initial investment ranging from under $1 million to $3-6 million dependent on the company’s stage of development. The firm can allocate up to $16 million (20% of total) over the lifetime of a company. The firm invests in early-stage therapeutic companies worldwide, with a focus on opportunities in North America.

The firm only invests in therapeutics, and are primarily focused on companies with preclinical or clinical assets. Within therapeutics, all modalities are of interest. The firm may invest up to 18 months prior to IND, however require that a company has a lead asset that has been characterized. The firm will consider opportunities in any indication area.

The firm invests in teams with experienced, highly motivated teams with a strong background in either life science research or industry. The firm only invests in companies with technology that has the potential to be first in class.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment firm based in Toronto, Canada is actively looking for new investments in the life science sector, especially medical technology. The firm’s second fund focuses on pre and post Series A investments and has the ability to do follow-on funding. The investment size can range from $100K to over $1M and up to $2-4M with follow-on funding. The capital structure is flexible, especially as they are currently raising their third fund. The firm typically co-invests and will lead investments depending on the occasion and size of the round. Investment can be in form of equity, whereas convertible loan and other capital structures will be considered. The new fund looks to invest in 10-20 companies. The firm focuses on companies based in Canada, but it will also look at opportunities in the US.

In the life sciences, the firm is currently looking for new investments in the medical technology, diagnostics, and healthcare IT sectors with a particular interest in medical devices with a software component. The firm is interested in all classes of medical devices and is indication agnostic. The firm is focused on preclinical to clinical stage technology and is focused on technology that requires an FDA regulatory pathway. Thus, the firm is not interested in wearables or consumer connected devices. The firm will consider therapeutics companies from time-to-time, however, therapeutics is not the firm’s focus.

The firm focuses on investments in private companies with an experienced management team and growth potential. The firm will take a board seat based on case-by-case basis, though is not the requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A major Chinese pharmaceutical company is looking for any potential drug candidates that align with the company’s strategy. The firm is seeking to strengthen its R&D/manufacturing capability and portfolio/pipeline and is open to all kinds of collaboration models, including straight licensing, co-development, contract selling, equity investment, and M&A. The company is currently looking for assets globally with a focus on the US and Europe.

Early stage products or platform technology with high potential or clear differentiation in the following areas: Oncology, Neurology, Cardiovascular & Cerebrovascular, Rheumatology and Inflammation, Respiratory Diseases, Infectious Diseases (except HIV), and Pediatric Diseases (except rare disease).  In addition, the firm is exploring emerging areas in oncology, such as immunotherapy, cell therapy, and precision medicine. In medical technology, the firm is interested in liquid biopsy, cancer diagnostics, and next generation sequencing, and would consider in-development and products.

The firm is looking for companies with capacity and experience in implementing R&D plans. The firm is interested in assets from the US, Europe or other countries, and intends to introduce the product to the Chinese market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Singapore, with additional office in Silicon Valley, makes early up to expansion stage investments across several industries including healthcare. The investment size is highly variable depending on the stage of the company. The firm invests in companies in North America and Europe that has a market expansion strategy in Asia and/or Singapore. The firm is actively seeking new investment opportunities.

In the Life Sciences, the firm is currently seeking medical devices, synthetic biology
and HCIT. For medical devices, the firm is opportunistic in terms of subsectors and indications. The firm looks for devices that are ready for commercialization. The firm is currently not looking for drug development companies.

The firm seeks entrepreneurs who are passionate, driven and enthusiastic, with sustainable business models and ideas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A multinational biopharmaceutical corporation looks to invest in/partner with academic research and start-up companies for developing innovative therapies. The firm has established a number of partnering models, including a corporate venture fund. The firm also takes part in equity rounds, usually with rights attached. The firm is open to make co-development deals to help early-stage biotech companies, and is currently looking for new investment opportunities across the globe with a focus in North America, Europe, and Asia.

The firm is currently looking for innovative therapeutics and medical technologies targeting the following areas: Cardiovascular & Metabolic Diseases, Immunology & Inflammation, Neuroscience, Oncology, Rare Diseases, and Vaccines. The firm is also open to other life science technologies that may speed up the development process, including lab technology and drug development enabling technologies. The firm also seeks in-licensing products for development. Overall, the firm is open to all stages of development, as the firm has separate teams to encompass all phases of development from preclinical to commercial stages.

The firm collaborates, in multiple formats, with both privately held and public life science companies with experienced management teams, innovative technologies, and an established scientific unit.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An early stage fund focused on seed investment and incubation in the healthcare field is currently investing from its USD 30 M fund closed in 2015, backed by six Chinese healthcare and life science companies. The firm’s typical investment size range from USD 1-1.5 M and is open to leading or co-investing. The firm is currently seeking opportunities in China or US-based companies with a China angle.

The firm is looking for cutting edge platform technologies in sectors including therapeutics, medical devices, and diagnostics. The firm is agnostic to therapeutic indications. In terms of development stage, the firm focuses on startup teams with some preclinical validation.

The firm is looking for strong management teams with sector expertise. The firm aims to bridge between R&D and commercialization with a focus on China-based startup teams or US companies with a China angle. The firm may request a board seat on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com